1243. Semi-Quantitative Benefit-Risk Assessment for a New Quadrivalent Meningococcal Conjugate Vaccine (MenACYW-TT) in Individuals 2 Years of Age and Older

BACKGROUND: MenACYW-TT is a new quadrivalent meningococcal conjugate vaccine approved by the US FDA for use in individuals 2 years and older. We present the structured benefit-risk assessment conducted by Sanofi Pasteur in support of the initial biological license application for MenACYW-TT. METHODS...

Descripción completa

Detalles Bibliográficos
Autores principales: Neveu, David, Kürzinger, Marie-Laure, Chen, Aiying, Dhingra, Mandeep S
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2020
Materias:
Poster Abstracts
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7776410/
http://dx.doi.org/10.1093/ofid/ofaa439.1428

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7776410/
http://dx.doi.org/10.1093/ofid/ofaa439.1428

Ejemplares similares